RNAC
Cartesian Therapeutics, Inc.
Healthcare — Biotechnology
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Price History
Fundamentals
| Market Cap | $299.10M |
| P/E Ratio (TTM) | - |
| Forward P/E | -3.80 |
| EPS (TTM) | $-5.80 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | -92.90% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $34.57 |
| Analysts | 7 |
| Next Earnings | Aug 6, 2026 BMO |
| Indexes | - |
Technical Indicators
| RSI (14) | 67.1 |
| Beta | 0.78 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $15.57 |
| 52-Week Low | $5.60 |
| 50-Day Avg | $7.75 |
| 200-Day Avg | $7.69 |
| Avg Volume | 172.1K |
| Volume | 37.7K |
Performance Analysis
NEUTRALRNAC presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:29 UTC
Back to Screener Export Report